Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2011-02-07

Clinical Trial Update: Study Evaluating Refacto For Pharmacovigilance

View source ↗

Summary

A completed pharmacovigilance study evaluating Refacto for Hemophilia A has posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Refacto (Factor VIII, recombinant)

Snippet

Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer | Conditions: Hemophilia A | Status: COMPLETED | Results posted: 2011-02-07